Compare Ginkgo Bioworks Holdings Inc (DNA) vs iShares Core S&P 500 ETF (IVV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs iShares Core S&P 500 ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while iShares Core S&P 500 ETF trades at $781.97 (market cap $897.20B). The key difference: iShares Core S&P 500 ETF is far larger — about 1174.9× Ginkgo Bioworks Holdings Inc's market cap, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and iShares Core S&P 500 ETF for 46 Days on average.
| DNA | IVV | |
|---|---|---|
Market Cap | $763.64M | $897.20B |
Volume | 3,204,177 | 4,580,672 |
Sector | Health | Broad Market / Factor |
52-Week High | $15.83 | $782.58 |
52-Week Low | $5.48 | $634.93 |
Typical Hold Time | 7 Days | 46 Days |
Enterprise Value | $865.59M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.00, up 13.34% today, with a bullish technical signal from moving averages. The company shows strong gross margins of 68.04% but remains unprofitable with a -219.6% net margin. Recent news includes a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnership expansions, though revenue declined to $132M in 2026.
DNA presents high risk with significant losses and cash burn, but analyst sentiment is divided with equal buy/sell ratings. Investment appeal hinges on future profitability from recent partnerships and government contracts, while current financials and negative cash flow pose substantial downside risk.
IVV, tracking the S&P 500, trades at $781.97 with a slight 0.18% daily gain. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. Recent news highlights mixed sentiment with concerns about profit growth slowing from 35% in 2026 to 15% in 2027 (24/7 Wall Street, 2026-10-03), though some analysts project a year-end rally (Citadel strategist, 2026-10-02). The ETF remains a core holding for broad market exposure amid ongoing economic uncertainties.
The outlook for IVV is cautiously optimistic, supported by bullish technicals and historical seasonal patterns. Key opportunities include potential upside from AI-driven earnings growth and index composition changes like Twilio's addition (Market Watch, 2026-10-01). Risks center on concentration in top holdings, rising interest rates, and geopolitical tensions that could dampen broader market performance. Investors should weigh the ETF's low-cost diversification against macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →
